<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04631406</url>
  </required_header>
  <id_info>
    <org_study_id>NR1-02</org_study_id>
    <nct_id>NCT04631406</nct_id>
  </id_info>
  <brief_title>A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)</brief_title>
  <official_title>A Phase 1/Phase 2a Safety and Tolerability Study of Intracerebral Transplantation of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS) and Early Evaluation of Potentially Useful Efficacy Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gary Steinberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Institute for Regenerative Medicine (CIRM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the safety and tolerability of escalating doses of NR1 administered&#xD;
      intracerebrally at a single time-point post-injury to subjects with chronic ISS with or&#xD;
      without cortical stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of the safety and tolerability of escalating doses of NR1 administered&#xD;
      intracerebrally at a single time-point post-injury to subjects with chronic ISS with or&#xD;
      without cortical stroke. The study will be a dose escalation using up to 4 cohorts each at a&#xD;
      single dose level, of intracerebral administration of NR1 cells. Secondary objectives are to&#xD;
      evaluate clinical and radiologic responses as well as utility of efficacy measurement tools.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>0-12 months</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fugl Meyer (FM) motor score</measure>
    <time_frame>0-12 months</time_frame>
    <description>Change in neurologic functional outcome to evaluate efficacy post-injection as defined by change in Fugl Meyer motor score in comparison to baseline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Neural Stem cells injected intracerebrally</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject cohorts will be treated with increasing doses of Neural Stem Cells injected intracerebrally using a traditional 3+3 trial design</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Neural Stem Cells</intervention_name>
    <description>NR1 is a human embryonic stem cell (hESC) derived product for the treatment of chronic ischemic subcortical stroke</description>
    <arm_group_label>Neural Stem cells injected intracerebrally</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 - 75 years&#xD;
&#xD;
          -  History of ischemic subcortical stroke in the middle cerebral artery and/or&#xD;
             lenticulostriate artery 6 to 60 months from time of stroke&#xD;
&#xD;
          -  Ability of subject to understand and provide written Informed Consent&#xD;
&#xD;
          -  Willing to take tacrolimus (Prograf) 2 days before and for 2 months after transplant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stroke lesion less than 1 cubic centimeter or greater than 100 cubic centimeters&#xD;
             measured by MRI&#xD;
&#xD;
          -  Index stroke is lacunar infarct less than 1 year old&#xD;
&#xD;
          -  History or presence of any major neurological disease&#xD;
&#xD;
          -  History of active cancer other than basal or squamous cell skin cancers&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary K Steinberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, Neurosurgery Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Research Coordinator</last_name>
    <phone>650-723-0508</phone>
    <email>stemcellstudy@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Health Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research Coordinator</last_name>
      <email>stemcellstudy@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Steinberg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Gary Steinberg</investigator_full_name>
    <investigator_title>Professor and Former Chair, Department of Neurosurgery, School of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

